DFM Platform
DFM Funding Monitor

A pioneer clinical trial management system to automatically collect, review and analyse prospective clinical trial data to prompt faster development of novel therapies.broad

YL System · Horizon Europe grant · 2022-09-01–2025-02-28

EC contribution

€2,496,243

Total cost

€3,566,061

Beneficiaries

1
About the data

Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2021-ACCELERATORCHALLENGES-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2021-ACCELERATORCHALLENGES-01-01. CORDIS record →

Objective

YonaLink (YL) is an Israeli company established in 2018 with the mission to disrupt the €46B clinical research market by connecting the world of Prospective Clinical Trial Data. To this end, YL is developing the YL System, a platform to migrate clinical research data saved in the patient health records, from medical centres to research database(s) in an automated, secure, validated, trusted and error-free way. The company has secured over €1.8M in the development of the YL System, reaching TRL 7 with pilot trials implementing it at Soroka MC (Clalit Health Insurance leading hospital) and in Sheba MC. The trials have confirmed the accuracy in migrating patients’ de-identified data from the EHR to the trial DB. EIC support will allow YL to finish optimization and validate the YL System in a multicentre–multinational pilot, demonstrating the advantage of automatic data transfer from EHR to the prospective trial database to all the clinical trial stakeholders in the EU.

Beneficiaries (1)

OrganisationCountryRoleEC contributionSME
YONALINK LTD IL coordinator €2,496,243 Yes

Get the DFM funding briefing — free

New EU defence calls, tenders and awards in your inbox.

Countries
Sectors
Sources

We store your email only to send the DFM briefing/alerts and to add you to DFM Analysis. Unsubscribe anytime.

Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.